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Abstract 
Shared decision making (SDM) means that clinicians and the patient make decisions about the 
treatment together. Regarding drug treatment in eating disorders (EDs), such decisions may 
include psychopharmacological treatment for the ED itself, medications for potential co-morbid 
psychiatric disorders, pharmacological strategies to alleviate the health consequences of an ED 
or “pro re nata” (PRN) medication which is given in acute care when required. 
Decisions regarding drug treatment in EDs should be specific in terms of the active 
pharmacological substance, its dose, its route of administration and the duration of treatment. 
Decisions should be made with regard to the specific health risks of patients with EDs and the 
entire treatment approach, and should take alternative measures, additional therapies and 
specific combinations of therapies into account. 
The differences in the expectations of patients, carers and clinicians towards drug treatment, 
the lack of specific suggestions in clinical practice guidelines and the lack of approved 
psychopharmacological treatment options make SDM necessary, but also a challenge.  
However, SDM may be limited due to the patient’s impaired insight or limited capacity due to 
the ED. Thus, the legal framework must be taken into consideration. 
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Shared decision making 
Introduction: Patients have traditionally entrusted decision-making to physicians. However, 
during the past several decades, patients have demanded increasing participation in decision 
processes and have also been encouraged to have a more active role in decisions concerning 
their health, as they are the ones who have to live with the consequences of medical decisions 
(Lin & Fagerlin, 2014). “Shared decision making” (SDM) means that clinicians and a patient 
make decisions about the patient’s care together, guided by research evidence, the clinical 
expertise of the clinician and the patient's values and preferences. Thus, SDM is crucially 
different from the paternalistic approach in which patients are expected to follow the clinicians’ 
advice. SDM is currently considered fundamental to informed consent and patient-centered care 
(Towle & Godolphin, 1999; Weston, 2001; Friesen-Storms et al., 2015). 
As the number of SDM publications in scientific journals has increased in recent years, SDM 
has been making headway in healthcare policy (Légaré & Thompson-Leduc, 2014). In the 
United States of America (US), for example, policy driven initiatives such as the Patient-
Centered Medical Home and the Affordable Care Act have reinforced the importance of 
implementing SDM across the health care continuum (Sia et al., 2004). In the United Kingdom 
(UK), health authorities have engaged clinical champions and patient representatives in national 
initiatives for SDM and embarked on a process of widely disseminating patient decision aids; 
and in Germany, patient information and SDM are embedded in social health insurance 
programs (Coulter et al., 2011; Harter et al., 2011). 
Various models with differing advantages and disadvantages in terms of practical applications 
have been described in the literature (Charles et al., 1997; Charles et al., 1999; Makoul & 
Clayman, 2006; Coulter, 1997). The integrative model of treatment decision making proposed 
by Makoul and Clayman (Makoul & Clayman, 2006) highlights essential elements of SDM, 
including discussion of the problem, the options, the benefits and risks, the individual values of 
the patients and their preferences, and the patient’s ability to follow their treatment plan. It 
emphasizes that physicians need to share knowledge and recommendations, check and clarify 
the understanding of patients, and make or explicitly defer decisions and arrange follow-up 
meetings for SDM. 
SDM for drug treatment in EDs: The clinical purpose of SDM is to improve the care of patients 
by encouraging the production and dissemination of accurate, balanced, understandable 
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information and increasing patient participation in their care. SDM interventions have been 
shown to improve patient understanding of the available treatment options, increase the 
proportion of patients with realistic expectations in terms of benefits and risks, stimulate patient 
involvement in decision making, and improve agreement between patient values and treatment 
options (Stacey et al., 2011; Lin & Fagerlin, 2014). Incorporating patient preferences into the 
decision-making process may also lead to improved patient well-being through improved 
adherence to treatment, fewer concerns of illness, and higher satisfaction with health outcomes 
(Greenfield et al., 1988; Kaplan et al., 1989; Lin & Fagerlin, 2014). 
The implementation of SDM has gained considerable interest, specifically in areas lacking 
strong and specific treatment recommendations (Friesen-Storms et al., 2015). This is, 
unfortunately, the case in EDs. Additionally, there appears to have been no specific research on 
SDM in drug treatment for EDs, therefore, this article will refer to aspects generally considered 
to be important in SDM on drug treatment in the current literature. These aspects are to provide 
up-to-date, evidence-based and independent information on drug characteristics that are 
relevant to doctors and patients, including information on mechanisms of action, mode and 
frequency of administration, clinical efficacy, side effects, and safety monitoring (Jongen, 
2018). The information in this article will be restricted to what is important and practically 
applicable. 
 
Medications used in patients with EDs 
Drug treatment for EDs: The main ED diagnoses according to DSM-5 are anorexia nervosa 
(AN), bulimia nervosa (BN) and binge eating disorder (BED) (American Psychiatric 
Association, 2013). For all three diagnoses, there are only two approved drugs: fluoxetine is 
approved for the treatment of BN and lisdexamphetamine (LDX) is approved for BED in the 
US (Himmerich & Treasure, 2018). As there is no single approved drug treatment option for 
AN, this is the ED diagnosis for which SDM on medication is most challenging. Therefore, 
SDM in AN will be a main focus of this article. 
Compared with other psychiatric disorders, including depression or schizophrenia, having only 
two approved medications for the entire group of disorders is a severe limitation in the 
management of EDs. In current textbooks of psychopharmacology, there are ~30 
antidepressants and a similar number of antipsychotics available for patients with depression 
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and schizophrenia, respectively (Benkert & Hippius, 2017; Taylor et al., 2018). The lack of 
approved psychopharmacological treatment may contribute to the poor outcomes in treatment 
of EDs. In AN, for example, where no approved drug treatment option is available, outpatient 
interventions usually fail to achieve weight restoration in the clear majority of patients (Guarda, 
2008); only ~30% of patients with AN having recovered after 9 years and the majority of 
patients with BED remain obese (Eddy et al., 2017). Therefore, there is an urgent need for 
further treatment options including psychopharmacological treatment. However, randomized 
controlled trials (RCTs) often fail as a considerable number of patients with AN refuse to 
participate in an RCT or drop out prematurely. One of the problems facing 
psychopharmacological research in AN may be the reservations patients have regarding drug 
treatment in general, particularly for drugs which may increase weight (Miniati et al., 2016). 
According to a recent review on psychopharmacological advances in EDs (Himmerich & 
Treasure, 2018), medications that are currently discussed to potentially help those with AN 
include atypical antipsychotics, cannabinoid receptor agonists, and N-methyl-D-aspartate 
receptor agonists. Fluoxetine as a serotonergic antidepressant which is approved for the 
treatment of BN. Positive study results have also been published for glutamatergic agents and 
μ-opioid receptor antagonists in BN. However, these medications have not received approval 
by major agencies for the evaluation of drugs and medicinal products, including the European 
Medicines Evaluation Agency (EMEA) or the US Food and Drug Administration (FDA). LDX 
is a prodrug of amphetamine which has been approved by the FDA for the treatment of BED. 
Table 1 gives an overview of the medications that are currently discussed to potentially help 
those with EDs. Despite the lack of approved drug treatment options in EDs, based on the 
current literature, it appears that >90% of inpatients with EDs are prescribed at least one 
psychopharmacological medication, >50% are prescribed two or more psychopharmacological 
drugs (Gable & Dopheide, 2005), and ~50% of inpatients additionally receive “pro re nata” 
(PRN) medication, which is given additionally when required (Tyrrell-Bunge et al., 2018). 
Drug treatment for co-morbid psychiatric disorders: EDs are often accompanied by other mental 
health disorders, including depression, anxiety, attention deficit/hyperactivity disorder, 
obsessive compulsive disorder, schizophrenia and personality disorders (Ulfvebrand et al., 
2015, Miniati et al., 2018; Link et al., 2017; Martinussen et al., 2017; Himmerich & Treasure, 
2018). These disorders often make psychopharmacological treatment with antidepressants or 
antipsychotics advisable or necessary (Tseng et al., 2017; Himmerich & Treasure, 2018; 
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Benkert & Hippius, 2017; Leblé et al. 2017). 
Patients with BED and BN are significantly more likely to be life-time smokers than healthy 
controls (Solmi et al., 2016). Patients with EDs who smoke may need drug treatment for 
smoking, if they are treated in a smoke-free hospital. In the UK, for example, all National Health 
Service (NHS) trusts introduced smoke-free regulations prohibiting smoking on all NHS sites 
in December 2006. Therefore, patients with EDs should be offered nicotine replacement therapy 
to assist them to stop smoking. However, there appear to be no reports on nicotine replacement 
therapies in patients with EDs, nor of any report on how smoking affects drug treatment in EDs. 
Drug treatment for health consequences of EDs: In patients with EDs, not only 
psychopharmacological drugs are prescribed, but often the health consequences of an ED also 
require drug treatment. The health consequences of AN include changes in laboratory 
parameters, including hyponatremia, hypokalemia, hypochloremia, hypomagnesaemia; low red 
and white blood cell counts indicating malnutrition; a lack of vitamins, including thiamine; a 
lack of certain nutrients, including iron, and problems of electrolyte balance (Himmerich et al., 
2010; Winston et al., 2000; Winston, 2012). Health consequences affecting the cardiovascular 
system include mitral valve prolapse, supraventricular and ventricular dysrhythmias, long QT 
syndrome, orthostatic hypotension, low blood pressure and congestive heart failure (Spaulding-
Barclay et al., 2016; Meczekalski et al., 2013; Sánchez-Muniz et al., 1991). Many patients with 
AN suffer from severely impaired bone health in terms of osteoporosis (Meczekalski et al., 
2013), which may lead to bone pain and collapsed or fractured vertebral bodies. Severe 
dehydration, which can result in kidney failure, and hypothermia are also typical consequences 
of AN (Stheneur et al., 2014; Williams et al., 2008). Refeeding can also cause a prolonged QTc 
interval, tachycardia, congestive heart failure with edema, and arrhythmias related to 
hypokalemia (Casiero & Frishman, 2006). Water loading by the patient to manipulate weight 
to feign treatment success can also cause severe electrolyte disturbances (Winston, 2012). 
The health consequences of BN include electrolyte imbalances as a result of purging behaviors 
(Franke et al., 2010). These electrolyte changes can lead to cardiac arrythmias and heart failure 
(Sachs & Mehler, 2016). Further potential health consequences of BN include rupture of the 
esophagus or the stomach during periods of bingeing and purging, inflammation, Barrett’s 
syndrome and adenocarcinoma of the esophagus (Sachs & Mehler, 2016), erosive gastritis, 
duodenal ulcers (Cuellar et al., 1988), and constipation as a result of laxative abuse (Sachs & 
Mehler, 2016). 
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BED often results in obesity and its associated health risks which include high blood pressure, 
high cholesterol and triglyceride levels, hypophosphatemia and type II diabetes mellitus (da 
Luz et al., 2018; Weschenfelder et al., 2018). 
Therefore, EDs can lead to malnutrition or obesity and can affect fluid and electrolyte balance, 
the metabolic and the cardiovascular system, the gastrointestinal tract and bone health. Health 
problems in these areas are often treated with medications, if acute fluid replacement and 
appropriate nutritional support are not sufficient for their treatment. Table 2 gives an overview 
of commonly used drugs for those suffering from the consequences of EDs in these systems of 
the body. 
Drug treatment for other acute or chronic health problems: Patients with EDs may suffer from 
health conditions which may not necessarily be related to the ED. However, these conditions 
may contribute to or complicate the ED and its treatment. An example is type 1 diabetes in 
patients with AN (Nielson et al., 2002), as the coexistence of type 1 diabetes and AN results in 
an increased incidence of diabetic complications, including retinopathy and nephropathy, 
presumably due to blood glucose being difficult to control in those with diabetes and comorbid 
AN (Brown & Mehler, 2014). In patients with AN and BN, poor diabetic control is often 
associated with omissions of insulin to avoid weight gain and other failures in adherence to the 
treatment regime (Szmukler, 1984). 
 
Treatment goals for drug treatment in EDs 
Doctors, vs. patients goals: There is a lack of research regarding the question of what 
psychiatrists, medical doctors, psychotherapists and other clinicians consider their goals in the 
treatment of patients with EDs. Therefore, it must be assumed that the primary outcomes of 
RCTs in EDs reflect the clinicians’ opinion on meaningful drug treatment outcomes. Usually, 
a decrease in EDs symptoms is considered a treatment goal. In AN, an increase in body mass 
index (BMI) and a decrease in AN symptoms are usually the goals of psychopharmacological 
treatment (Miniati et al., 2016; Dold et al., 2015). However, from a patient perspective, they 
may feel such a trial and such psychopharmacological treatment were just a way to speed up 
weight gain for the clinicians’ benefit, rather than for helping their thinking and anxiety, and 
that numbers and weight is all that is important for those ’higher up’ (Tyrrell-Bunge et al., 
2018). 
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Patient Reported Outcome Measures (PROMs) and Patient Reported Experience Measures 
(PREMs): In the context of a quality improvement project on a specialist unit for EDs, Tyrrell-
Bunge et al. 2018 surveyed patients with AN on their perspective and treatment goals for 
psychopharmacological treatment (Tyrrell-Bunge et al., 2018). Over 50% of the patients said 
they would find medication useful if it helped reduce anxiety or sleep problems. In 83% of 
patients, weight gain as a possible side-effect of drug treatment for AN was a concern (Tyrrell-
Bunge et al., 2018). Therefore, as the fear of weight gain is a symptom of the disorder 
(American Psychiatric Association, 2013), patients suffering from AN do not want a medication 
that leads to weight gain which, in contrast, is one of the main treatment goals of the doctors. 
The psychiatrist and the ward teams should not collude with the disorder and agree with the 
patient that the side effect of weight gain should be avoided; a medication that helps to reduce 
the disordered eating behavior and thinking may also offer a reduction of anxiety or help with 
sleep problems may be a desirable benefit from the patient’s perspective (Tyrrell-Bunge et al., 
2018). 
The inclusion of PROMs and PREMs into the individual treatment goals and into the outcome 
criteria for RCTs is sensible, as the patient should be aware of the benefit of a treatment prior 
to deciding to consent to a drug treatment for an ED. PROMs and PREMs assess the efficacy, 
safety, and experience of care from a patient perspective. Such PROMs and PREMs regarding 
anxiety and sleep problems in addition to BMI are likely to be of benefit from a patients’ 
perspective and may improve the willingness to consent to psychopharmacological treatment 
for AN or to participate in an RCT (Tyrrell-Bunge et al., 2018). 
Agreeing on common treatment goals and their measurement: A psychopharmacological 
treatment is only sensible if treatment success is measurable. Therefore, the SDM process 
should include an agreement on how treatment success will be gauged. Information on available 
measurements should be shared between the treating physician and the patient. The available 
measurements and questionnaires are explained below. 
 
Clinical practice guidelines for drug treatment in EDs 
Due to the lack of pharmaceutical RCTs in EDs and thus a lack of evidence on 
psychopharmacological treatment for EDs, clinical practice guidelines (CPGs) for patients with 
EDs are not able to provide clinicians and patients with optimal treatment recommendations. 
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They mainly provide generic advice without discussing specific drugs. 
The National Institute for Health and Care Excellence (NICE) guidelines, for instance, state 
that one should not offer medication as the sole treatment for EDs. They advise clinicians to 
take into account the impact malnutrition and compensatory behaviors can have on medication 
effectiveness and the risk of side effects, to assess how the ED will affect medication adherence, 
to be aware of the risks of medication that can compromise physical health due to pre-existing 
medical complications, and to offer ECG monitoring for patients with an ED who are taking 
medication that could compromise cardiac functioning. Additionally, NICE guidelines briefly 
mention EDs and medication misuse (NICE, 2017). However, NICE guidelines do not 
recommend a specific medication or group of medication for any ED. 
“The Management of Really Sick Patients with Anorexia Nervosa” (MARSIPAN) are specific 
guidelines in the UK for patients with severe AN who are admitted to general medical units. 
They provide advice to the primary care teams, criteria for admission to both medical units and 
specialist ED units and to non-specialist psychiatric units, criteria for transfer between services, 
and advice on the required members of the inpatient medical team. They also include 
information about the medical, nutritional and psychiatric management of patients with severe 
AN in medical units, including the appropriate use of the mental health legislation (The Royal 
Colleges of Psychiatrists, Physicians and Pathologists, 2014). However, these guidelines do not 
make specific recommendations about drug treatment; they rather give advice whom to involve 
for treatment decisions. 
 
Aspects of drug treatment in EDs which warrant decisions 
Comprehensive treatment strategy: The question of which drug to choose depends on whether 
treatment is indicated in general, and whether drug treatment should be considered at all. If drug 
treatment is considered, this psychopharmacological treatment should always be embedded in 
a comprehensive treatment concept (Benkert & Hippius 2017). Depending on the treatment 
setting, all parties involved should help to reach a decision on the treatment strategy. In an 
inpatient ward, for example, this will involve the patient, their carers, medical doctors, 
psychotherapists, nurses, family therapists, occupational or music therapists, physiotherapists, 
and pharmacists. The general and comprehensive treatment concept for a patient with an ED 
must fit the medication in question. D-cycloserine (see Table 1), which is not approved for the 
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treatment of AN has only been tested in a study where patients with AN received additional 
exposure therapy (Levinson et al., 2015). Therefore, it can only be concluded from this study 
that D-cycloserine improves the results of exposure therapy for AN, but not that it would lead 
to weight gain by itself in this patient group. 
Multidisciplinary competence: In EDs, specialists of several medical disciplines are involved. 
For a psychiatrist, it is appropriate to prescribe psychopharmacological drugs, including 
olanzapine, fluoxetine or LDX (see Table 1). However, the consequences of an ED, for 
example, treatment-resistant osteoporosis as a consequence of AN or type 2 diabetes as a 
consequence of BED, may warrant the prescription of insulin-like growth factor 1 or insulin 
(see Table 2). Therefore, an endocrinologist is appropriate to prescribe these medications. 
Prescriptions should also be supervised by a pharmacist who understands the medications 
prescribed for a patient to evaluate potential interactions between drugs.  
In inpatient or day-hospital settings, nurses usually contribute substantially to SDM on 
medication. In addition to their medical knowledge, nurses are able to provide information on 
the availability of a medication on the ward, how it needs to be stored, how it can be given to a 
patient, and what the local guidelines for prescription and documentation entail.  
Dosage and timeframe: The doses of medications used in EDs may vary from the doses used in 
other disorders. Olanzapine is such an example; it is not approved for the treatment of AN but 
for schizophrenic disorders. The recommended starting dose for acute treatment of 
schizophrenia is 10 mg/d (Benkert & Hippius, 2017), whereas the majority of studies 
investigating olanzapine in patients with AN (Kafantaris et al., 2011, Brambilla et al., 2007, 
Bissada et al., 2008, Attia et al., 2011), initiated olanzapine treatment at 2.5 mg/d and increased 
this dose slowly to 5 or 10 mg/d (for review see Himmerich & Treasure, 2018). However, in 
clinical practice in adolescent psychiatry, the starting dose is often 1.25 mg/d (Spettigue et al., 
2008). Therefore, a dosage between 1.25 and 10 mg/d is often used for the treatment of AN. 
Regarding the dosage, it should be noted that prescribing guidelines, including the British 
National Formulary (BNF) cite caution for people with a slower metabolism and female 
patients. Thus, in patients with AN a slow up-titration schedule of 1.25 mg/d increments each 
week for adolescents and 2.5 mg/d for adults up to a maximum of 10 mg/d for both adolescents 
and adults is recommended. The same caution applies to down-titration (Joint Formulary 
Committee, 2018). Thus, plans need to be made on the starting dose, the up-titration schedule, 
the dose for acute therapy and maintenance and down-titration. In relation to the treatment dose, 
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the timeframe for the different dosages needs to be determined. 
However, due to the lack of evidence for the majority of medications used for the treatment of 
EDs, it is difficult to obtain sufficient information concerning the dose and the necessary 
treatment duration form the scientific literature. Strictly speaking, evidence-based guidelines 
for the pharmacological treatment of EDs are only available for LDX and fluoxetine 
(Himmerich, Treasure 2018). 
Administration and dispensing: As shown in Table 1 and Table 2, there is a variety of routes 
of administration for medications to treat EDs and their health consequences. Olanzapine, for 
example, an antipsychotic that has been investigated to treat AN (Himmerich & Treasure, 2018) 
can be administered orally or intramuscularly. Insulins are injected subcutaneously, and 
estrogens can be applied orally or as transdermal patches. Severe electrolyte disturbances may 
require intravenous application of potassium or magnesium, and constipation may be treated by 
rectal glycerine application (see Table 2). Decisions also have to be made on dispensing, 
depending on whether the patient can take the medication autonomously, whether they are – 
due to their illness – restricted in taking their medication regularly, or whether the 
administration route is reserved for professional administration, for example an intravenous 
application. A patient with an ED may need the help of a nurse, a physician or a pharmacist for 
regular intake of their medication. 
 
Information to be shared 
Evidence and measurement of treatment success: To share evidence on drug treatment in EDs 
is a challenge for clinicians, as fluoxetine is the only EDs medication that is approved in most 
countries. For AN, there is no approved drug treatment, as mentioned above. Therefore, the 
prescribing psychiatrist must summarize the evidence from single studies in a comprehensive 
manner. 
If a psychiatrist wants to discuss olanzapine with a patient with AN, they could, for example, 
explain in an intelligible manner that scientific literature suggests that olanzapine is the atypical 
antipsychotic with the highest likelihood to restore weight and treat important psychological 
and emotional symptoms in patients with AN in a safe manner: i) olanzapine was superior to 
placebo with regard to weight gain in four published RCTs (Kafantaris et al., 2011, Brambilla 
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et al., 2007, Bissada et al., 2008, Attia et al., 2011) and in one not yet published but recently 
completed large, multisite RCT in patients with AN (mentioned in Davis & Attia, 2017); ii) 
olanzapine may be the most efficacious of antipsychotics examined for the treatment of AN due 
to its known beneficial influence on anxiety (Tollefson & Sanger, 1999; Temmingh & Stein, 
2015) and sleep (Kluge et al., 2014); and iii) it affects the serotonergic, dopaminergic and 
histaminergic neurotransmission and thus may have a beneficial effect on the self-regulatory, 
the hedonic and the homeostatic system which have all been shown to play a crucial role in the 
pathophysiology of EDs (Himmerich & Treasure, 2018). 
During SDM, the clinicians should also share information on how treatment success will be 
measured. Using the example of olanzapine treatment for AN, treatment outcomes could be the 
BMI, ED and general psychopathology, treatment adherence, and patient and carer quality of 
life. BMI can easily be measured using a measuring tape and a scale. Questionnaires to gauge 
ED psychopathology, the Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS) or the 
Eating Disorder Examination-Questionnaire (EDE-Q) could be used. The YBC-EDS is an 
interview assessing core preoccupations and rituals associated with EDs. It allows for 
assessment of the severity of symptoms independent of the content of the symptom experienced 
or exhibited (Mazure et al., 1994). The EDE-Q is a questionnaire assessing key behavioural 
features and associated psychopathology of EDs, which includes four subscales: Restraint, 
weight concern, shape concern, and eating concern (Luce & Crowther, 1999). General 
psychopathology could be assessed using, for example, the Brief Psychiatric Rating Scale 
(BPRS) which assesses 24 different psychiatric symptoms (Overall & Gorham, 1962). 
Potential side effects and safety measures: In addition to beneficial aspects, potential side 
effects and measures to control measures also need to be explained. In the case of olanzapine 
prescription for AN, clinical outcome measures of adverse effects could be oriented towards 
the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological 
Treatment of Schizophrenia (Hasan et al., 2013), as olanzapine is approved for the treatment of 
schizophrenia. However, clinicians must also consider CPGs, including the NICE guidelines, 
which state the specific risks for prescribing medication in patients with EDs (see above; NICE, 
2017). Potential side effects can affect the metabolic system and thus require regular physical 
examinations including the measurement of weight, blood pressure, pulse and body 
temperature. Further possible side effects include disturbances of conduction within the heart 
which are measurable by ECG. As stated in the NICE guidelines, medication can compromise 
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physical health due to pre-existing medical complications. Disturbances in laboratory 
parameters are examples of such medical conditions, and olanzapine can lead to additional 
changes requiring the regular measurement of clinical-chemical parameters of electrolytes and 
the fluid balance, of the kidney and liver function, and of blood count. With regard to 
extrapyramidal side effects, certain scales such as the Simpson-Angus Extrapyramidal Side 
Effects Scale (SAS; Simpson & Angus, 1970) and the Barnes Akathisia Rating Scale (BARS; 
Barnes, 1989) are available. Similarly, sleepiness is a frequent symptom in patients with AN, 
(Lauer & Krieg, 2004; Della Marca et al., 2004) and a common side effect of antipsychotics, 
specifically olanzapine (Fang et al., 2016). Thus, a standardized measurement of sleepiness 
using the Epworth Sleepiness Scale (ESS; Johns, 1991) may be considered. To cover a broad 
range of side effects, clinicians could use the UKU-Side Effect Rating Scale (UKU-SERS; 
Lingjærde et al., 1987) which is a general rating scale for the registration of unwanted side 
effects of psychotropic medication.  
Table 3 provides a synopsis of important aspects of SDM on the prescription of medication in 
adult patients with an ED. 
 
Specific aspects of SDM in EDs 
Illness-related impairment in decision making: From a neurobiological perspective, decision 
making is a highly complex process involving multiple cortical areas and various 
neurotransmitter systems. Examples of involved brain areas include the orbitofrontal, the 
anterior cingulate, and dorsolateral prefrontal cortex. These are connected with each other as 
well as with other subcortical structures, including the limbic system, and are involved in 
different aspects of decision-making. For example, the orbitofrontal cortex is linked with limbic 
structures and involved in the process of emotional and reward-based decision making, whereas 
the dorsolateral prefrontal cortex and the anterior cingulate cortex are vital in intellectual and 
rational decision making (Rosenbloom et al., 2012). Food-related decisions do not only involve 
intellectual and rational decision making but are predominantly associated with an emotional 
and reward-based component which may be specifically impaired in patients with EDs (Frank 
et al., 2016).  
On the neurotransmitter level, dopamine plays a crucial role in reward-based and value-based 
decision making (Saddoris et al., 2015). Patients with AN, have been shown to have increased 
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dopamine receptor affinity which can affect reward mechanisms and thus impair reward-based 
decision making (Frank et al., 2005).  
Other neurotransmitters and hormones that have been reported to show alterations in patients 
with EDs include serotonin, norepinephrine, glutamate, opioid, cannabinoid, histamine, ghrelin, 
leptin, insulin, and glucagon-like peptide-1, and these changes are likely to influence decision 
making (Himmerich & Treasure, 2018). These signaling molecules are involved in emotion and 
appetite regulation, self-perception and cognition. Thus, it is understandable why an intense 
fear of weight gain is a core symptom of AN and why the majority of patients with AN do not 
want a medication that would lead to weight gain (Himmerich et al., 2018).  
It is also well known that the hypothalamus-pituitary-adrenal (HPA) axis is activated in AN. 
This may contribute to the above-mentioned neuroendocrine effects in AN, as the activated 
HPA axis interacts with limbic structures, including the insular and prefrontal cortices (Bou 
Khalil et al., 2017). These interactions may be responsible for curbing food intake during 
emotional stress (Ulrich-Lai et al., 2015). An activated HPA axis has also been shown to 
influence decision-making across different settings and circumstances (Guillaume et al., 2013; 
Singer et al., 2017). 
Therefore, patients are at risk of making decisions that are influenced by their illness (Arcelus 
et al., 2011). As a result, following the patient’s thinking risks the patient being left to a life 
ruled by the ED or succumbing to mortality in severe cases. 
Legal aspects: For patients who have impaired insight or limited capacity in decision making, 
drug treatment can be given under a relevant legal framework. In the UK, two pieces of 
legislation are relevant to drug treatment in EDs, namely the Mental Health Act (Department 
of Health, 2015) and the Mental Capacity Act (Department of Health, 2005). Patients who 
refuse treatment or lack the capacity to consent to treatment and are at risk of danger to 
themselves or others may be considered for compulsory treatment. This is particularly relevant 
in AN due to the severity of the illness which can affect the patients’ decision-making capacity 
and its association with a high mortality rate (Arcelus et al., 2011). However, the decision 
regarding whether the ED is of a nature and degree which precludes the patient from making 
informed decisions relating to their treatment can be difficult and, thus should not depend on 
the subjective clinical judgement of the psychiatrist. Therefore, in the UK, this decision is made 
jointly by an Approved Mental Health Practitioner, who takes the lead in this decision, and 
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usually a social worker, two independent psychiatrists and the closest relative of the patient 
(Department of Health, 2015). 
However, there are practical challenges in administering medication against a patient’s will. 
For example, some of the medications are only available in oral form and can be difficult to 
administer to refusing patients. For those that are available in intramuscular form, it can also be 
challenging as muscle atrophy is common in severe AN. Currently, there has been no research 
on the effect of compulsory drug treatment on patients with EDs, to the best of our knowledge. 
Therefore, it is important that patients are involved as much as possible in the decision-making 
process with relevant information (Table 3) provided to them; and the decision must be made 
in their best interest, balancing the risks and benefits of such treatment even if it is to be given 
without consent under legal frameworks. 
 
Discussion 
Summary: In summary, SDM is fundamental to informed consent and patient-centered care in 
EDs. There are currently immense difficulties in SDM in EDs, including limited research, the 
lack of approved psychopharmacological treatment options, and insufficient advice on the 
specific pharmacological drug treatment options from CPGs. Drug treatment in EDs is not 
restricted to the few discussed potential psychopharmacological treatment for EDs (Table 1), 
but also includes psychopharmacological treatment for comorbid disorders and drug treatment 
for the consequences of the ED (Table 2). Here, we have emphasized how important it is that 
clinicians and patients share their goals for the patients’ care and information on the history, 
symptoms, results of examinations, diagnoses and the characteristics of the medication in 
question; we have developed a synopsis of the most important aspects of SDM in drug treatment 
for patients with EDs (Table 3). 
However, this article only describes a collection of clinical issues that warrant clarification and 
in-depth research. Therefore, the following section aims to provide some trenchant comments 
from those involved in SDM in EDs, which may promote further discussion surrounding SDM 
for drug treatment in EDs. 
The psychiatrist’s perspective: From the perspective of a psychiatrist, SDM is a challenge in 
EDs due to the lack of evidence derived from RCTs. Although the SDM literature demands that 
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the clinicians share information on evidence, this evidence is almost not existent in EDs, with 
the exception of fluoxetine in BN and LDX in BED (Himmerich, Treasure 2018). AN, as an 
example of an ED, is characterized by ego-syntonic self-starvation, denial of illness, 
ambivalence towards treatment, treatment refusal and high drop-out rates (Guarda et al. 2008). 
Therefore, SDM with a patient who does not want to gain weight often feels like compromising 
with the disorder rather than helping the patient to lead an autonomous and self-paced life. 
CPGs, including the NICE guidelines, do not fully support the doctors’ reasoning to prescribe 
a medication; by contrast, they elicit and promote anxieties, as they only remind the doctors of 
the difficulties and risks rather than making positive recommendations. Therefore, SDM may 
feel like an obstacle that prevents psychiatrists from helping their patients with EDs, specifically 
if patients require PRN medication for a variety of consequences of the ED rather than accepting 
the one medication that may help to tackle the cause of these physical and mental consequences. 
In addition, psychiatrists are aware of the severe side effects of drug treatment having observed 
them during clinical practice, including massive weight gain leading to serious health risks 
(Himmerich et al., 2015), rhabdomyolysis (Himmerich et al., 2006) or live-threatening 
psychotic symptoms (Himmerich et al., 2003); no one individual wants to take full 
responsibility for these events. In addition, it is unlikely that a patient would want someone to 
make decisions on taking such serious risks on their behalf. Therefore, SDM is without any 
alternative. From a psychiatrist’s perspective, the question is not whether or not to use SDM, 
but rather what degree of responsibility are patients and their clinicians willing and able to 
accept during the process of SDM. 
The internist’s perspective: Patients with EDs, particularly those with AN, can be admitted to 
the emergency department or a medical ward for treatment of conditions that can be related to 
their ED or unrelated, e.g. infections, cardiovascular complications, or metabolic disturbances 
(Rome & Ammerman, 2003). Treatment can become difficult for several reasons, however, the 
most aggravating factors are legal uncertainties and medical teams not being set up to deliver 
specialized multidisciplinary care. 
Upon admission, patients are often unwell or unresponsive, and they are treated in their best 
interest. As soon as their condition improves, they often request discharge or limitations to their 
treatment; this puts the physician in a difficult position, as the complications arising from an 
ED can be potentially life-threatening, depending on the degree of their severity and nutritional 
status, and would ideally require prompt and adequate treatment, e.g. electrolyte replacement. 
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In order to decide whether the patient has the ability to make such a decision, a capacity 
assessment needs to be completed. Often, patients do have the capacity and, even when aware 
of the potentially life-threatening condition, they do not wish to receive treatment. Even in cases 
when the capacity assessment leads to the conclusion that the patient is lacking capacity, legal 
frameworks can make the administration of treatment difficult. In the UK, the physician has to 
decide whether to admit a patient with an ED, if it is necessary, in their best interest and as the 
least restrictive measure, against their will under the Mental Health Act (Department of Health, 
2015) or under the Mental Capacity Act (Department of Health, 2005). However, neither of 
those legal frameworks allows the immediate administration of medication against the patient’s 
will, and the physician is only allowed to monitor the patient’s condition. Having a patient 
legally admitted to a medical ward can negatively affect the patient-physician relationship and 
can hinder an SDM process. 
Another difficulty in the management of patients with ED on a general medical ward are the 
often limited resources and the non-specialized physicians and therapists. In the UK, the 
MARSIPAN guidelines (The Royal Colleges of Psychiatrists, Physicians and Pathologists, 
2014) recommend that hospitals which can admit severely ill patients with EDs identify a 
consultant physician with interests in managing EDs and nutrition to optimize inpatient care for 
those patients. However, this is not feasible for every hospital. For general physicians in 
emergency departments or on medical wards, it can be difficult to assess the severity of the 
condition of patients with EDs and to decide on appropriate treatment. Often, physicians can 
only offer treatment or dietitian’s review and advice. 
The patent’s perspective: From the perspective of the patient, the discussion of any form of 
treatment can cause anxiety for several reasons. It is often the case that the ED leads to a patient 
developing self-imposed rules and coping mechanisms, which influence their food intake or 
energy expenditure; these are challenged in both outpatient and inpatient treatment settings, 
which can cause distress. There can be a reluctance to change or engage with treatment, which 
may be related to denial of the illness or the negative stigma associated with EDs, or the anxiety 
felt when faced with parting from the ‘safety’ of what they know. 
Decisions regarding psychopharmacological treatment are equally anxiety-provoking. In the 
case of AN, in addition to the potential stress caused by taking the drug itself, patients may feel 
a sense that the most important treatment outcome from the view of healthcare professionals is 
weight gain, rather than providing support with the psychological or behavioral issues that cause 
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distress. Patients are faced with and have to bear the consequences of decisions surrounding 
medication, for or against inpatient treatment and around the mental health act. In contrast to 
the psychiatrist, this is not their area of interest or expertise. Therefore, patients often rely on 
the information given by other patients to obtain a second opinion on these matters. This 
introduces another challenge for SDM, particularly in an inpatient setting, as relationships 
established with other patients can encourage unhelpful thinking or behaviours reinforcing to 
the ED, introduce a sense of ‘competition’, or lead to decision-making based on the experiences 
of others. It is therefore important that SDM is sensitive to patient concerns and that the 
potential benefits of drug treatment, including reduced anxiety, improved sleep and the potential 
increased ability to engage with therapy, are also explained. This highlights the need for further 
evidence-based information to encourage patient inclusion, discussion and ultimately 
cooperation. The use of advanced directives could also be discussed for consideration, which 
can be made by a patient when they are well in the event of relapse. 
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Table 1: Medications that are currently discussed to potentially help people with EDs based on 
(Himmerich & Treasure, 2018; Dold et al., 2015; Levinson et al., 2015; Andries et al., 2014; Benkert & 
Hippius, 2017). The table shows the different drug classes, the active substances, their possible route of 
administration and their daily doses for the treatment of EDs in adults by oral administration as a tablet 
and their approval status. Natrexone has been tested using single doses prior to exposure therapy. 
Abbreviations: EDs, eating disorders; NMDA, N-methyl-D-aspartate; US, United States of America. 
 Drug class Active substance Available 
route of 
administration 
Dose Approval 
status 
Anorexia 
Nervosa 
Antipsychotic Olanzapine  Oral and 
intramuscular 
2.5-10 
mg/d 
Not 
approved 
Aripiprazole Oral and 
intramuscular 
5-15 mg/d Not 
approved 
Cannabinoid 
receptor agonist 
Dronabinol Oral 5-15 mg/d Not 
approved 
NMDA receptor 
agonist 
D-Cycloserine Oral 50-250 
mg 
Not 
approved 
Bulimia 
Nervosa 
Serotonergic 
antidepressant 
Fluoxetine Oral 20-60 
mg/d 
Approved 
Glutamatergic 
agent 
Topiramate Oral 12.5-200 
mg/d 
Not 
approved 
μ-Opioid 
receptor 
antagonist 
Naltrexone Oral 250 mg 
prior to 
exposure 
Not 
approved 
Binge 
Eating 
Disorder 
Amphetamine Lisdexamfetamine Oral 30-70 
mg/d 
Approval in 
the US 
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Table 2: Currently used or investigated medications to treat health consequences of EDs in adult patients 
(Jagielska et al., 2016; Misra & Klibanskia, 2011; McCallum et al., 2006; Winston et al., 2012, Winston, 
2000; Santonastaso et al., 1998). The table provides an overview of the problem area, potential health 
consequences, treatment strategies, active substances that may be used, and route of administration. 
With the exception of oral vitamin and electrolyte replacement, most of these medication strategies are 
only used when dietary measures fail. This table does not aim to provide a comprehensive summary, but 
to demonstrate the variety of drugs that may become necessary to treat the health consequences of EDs. 
Abbreviations: EDs, eating disorders; VRA, vasopressin receptor antagonist; GI tract, gastro-intestinal 
tract; GERD, gastroesophageal reflux disease; emerg., if emergency treatment is necessary; NSAID, 
non-steroidal anti-inflammatory drug. 
 Health problem Drug 
class/treatment 
strategy 
Active 
substance 
Route of 
administratio
n 
Malnutrition Vitamin deficiency Multivitamins Vitamins Oral (e.g. 
Forceval®) 
Vitamin B deficiency Vitamin B 
Compound 
B vitamins Oral (e.g. 
Vitamin B 
Compound 
Strong®) 
Thiamine (vitamin B1) 
deficiency 
Thiamine 
replacement 
Thiamine Oral, i.v. 
Iron deficiency Iron replacement Iron Oral 
Disturbances 
of the fluid 
and 
electrolyte 
balance 
Dehydration Fluid replacement Water and 
electrolytes 
Oral, i.v. 
Water loading VRAs in severe 
cases of water 
loading with 
hyponatraemia 
Conivaptan, 
Tolvaptan, 
Lixivaptan 
Oral, i.v. 
emerg. (VRAs 
not tested in 
EDs) 
Hyponatremia Sodium 
replacement 
Sodium Oral, i.v. 
emerg. 
Hypokalaemia Potassium 
replacement 
Potassium  Oral (e.g. 
Sando-K®), i.v. 
emerg. 
Persistent 
hypokalaemia 
Magnesium 
replacement 
Magnesium Oral, i.v. 
emerg. 
Persistent 
hypokalaemia and 
vomiting 
Proton pump 
inhibitors 
Omeprazole Oral, i.v. 
Hypochloraemia Sodium chloride, 
Saline solution i.v. 
Sodium chloride Oral, i.v. 
Hypocalcaemia Calcium 
substitution 
Calcium, 
vitamin D 
Oral: Calcium 
and vitamin D, 
i.v. calcium 
emerg. 
21 
 
 
Hypophosphataemia Phosphate 
supplementation 
Phosphate Oral (e.g. 
Phosphate-
Sandoz®) 
Hypomagnesaemia Magnesium 
supplementation 
Magnesium Oral, i.v. 
emerg. 
Endocrine and 
metabolic 
disorders 
Obesity Antidepressant and 
μ-opioid receptor 
antagonist 
Bupropion and 
naltrexone 
Oral 
(Mysimba®) 
GLP-1 analogue Liraglutide Subcutaneous 
injection 
(Saxenda®) 
Type 2 diabetes Oral 
hypoglycemics, e.g. 
Biguanides  
Metformin Oral (e.g. 
Glucophage®) 
Insulins Rapid-, short- or 
long-acting 
Insulins 
Subcutaneous 
injection (e.g. 
Humalog®, 
Lantus®) 
Hypercholesterolaemi
a 
Statins Atorvastatin Oral (e.g. 
Lipitor®) 
GI tract 
problems 
GERD Antacids Sodium 
alginate, sodium 
bicarbonate, 
calcium 
carbonate 
Oral (e.g. 
Gaviscon®) 
Proton-pump 
inhibitors 
Omeprazole Oral 
Abdominal discomfort Antispasmodics Mebeverine Oral (e.g. 
Colofac®) 
Gastroprokinetics Metoclopramid
e 
Oral (e.g. 
Maxolon) 
Constipation Non-absorbable 
sugar laxative 
Lactulose Oral 
Hyperosmotic 
laxatives 
Glycerine  Rectal 
Cardiovascula
r diseases 
Persistent hypotension Glucocorticoid Fludrocortisone Oral 
Impaired 
bone health  
Osteoporosis Minerals and 
vitamins 
Calcium and 
vitamin D 
Oral (e.g. 
Adcal-D3®) 
Hormones Oestrogens Oral, 
transdermal 
Insulin-like 
growth factor-1 
(e.g. 
Mecasermin) 
Subcutaneous 
Bisphosphonates Risedronate Oral 
Pain Pain associated with 
osteoporosis/GI pain 
NSAID Paracetamol Oral 
Axiety and 
sleep 
Anxiety and sleep 
disturbances 
Antihistamines Promethazine Oral, i.m., i.v., 
rectal 
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disturbances Sleep disturbances Nonbenzodiazepin
e hypnotic agents 
Zopiclone Oral  
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Table 3: Synopsis of important aspects of SDM on drug treatment in adult patients with an ED based 
on (Makoul & Clayman, 2006; Stacey et al., 2011; Lin & Fagerlin, 2014; Himmerich & Treasure, 2018; 
Benkert & Hippius, 2017; Taylor et al., 2018; National Institute for Health and Care Excellence [NICE], 
2017; The Royal Colleges of Psychiatrists, Physicians and Pathologists, 2014; Joint Formulary 
Committee, 2018). For further references, see text. The information may be obtained in preparation for 
or during an SDM meeting. Such a meeting may be a ward round meeting, a Care Programme Approach 
meeting or a separate meeting. Abbreviations: SDM, shared decision making; MHA, Mental Health Act; 
GP, General Practitioner. 
Legal aspects needing clarification prior to SDM  
• Legal framework of the treatment (voluntary vs. compulsive treatment, e.g. under MHA) 
• Capacity of the patient 
Individuals involved in the SDM process 
• Patient 
• Carers 
• Physicians (medical doctors of different specialties) 
• Nurses (mental and physical health nurses) 
• Therapists (psychotherapists, occupational/art/music therapists, physiotherapists) 
• Dietitians 
• Pharmacy 
• GP team, home treatment team, specialist treatment team 
• If necessary, representatives of insurances or health services 
Information to be shared by patient with help of clinicians 
• Individual treatment goals 
• Current problem(s) and/or symptom(s) they want help with 
• Their values and preferences 
• Information about current risk-taking behaviours, including vomiting, laxative abuse, water 
loading 
• Mental and physical health problems, social and family history 
• Current and previous medication and nutritional supplements 
• Smoking status, use of illicit drugs 
• Dietary habits that may influence drug metabolism (e.g. grapefruit juice) 
Information to be shared by family, GP and home treatment team 
• Previous and current difficulties at home 
• Experience with previous medicinal treatments 
• Available support for prescription, administration and intake of medication 
Information on health and current treatment of the patient to be shared by the clinicians 
• General psychopathology and eating disorder psychopathology 
• Physical health problems (gastro-intestinal tract, metabolic system, cardiovascular system, 
bones, kidneys, brain) 
• Body weight, blood pressure, pulse, body temperature 
• Changes in laboratory parameters 
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• Results of ECG and other examinations 
• Refeeding problems 
• Current medication, nutritional supplements and treatment 
• Clinical observations, including adherence to meal plan and risk-taking or disorder-related 
behaviours 
• Summary of history taking, physical examination, symptoms detected, clinical observations 
made and diagnoses suggested or established 
Information on the treatment options to be shared by the clinicians 
• Treatment goals of the clinicians 
• Available treatments 
• Medicinal, naturopathic and psychological treatment alternatives 
• Advice from guidelines 
• Evidence from scientific literature 
• Own clinical experience 
• Benefits 
• Side effects and risks 
• Interactions with current and potential future drugs and treatments 
• Measurements of treatment success and side effects 
• Realistic perspective 
Decisions to be made 
• Common treatment goals 
• Comprehensive treatment concept 
• Problem(s) or symptom(s) that need drug treatment 
• Prescriber (prescribing within limits of competence) 
• Medication 
• Application 
• Administration 
• Length of treatment 
• Monitoring and precautionary measures 
• Measurement and documentation of treatment success and side effects 
• Follow-up meeting to evaluate impact of decision 
Duties of the clinicians during SDM process 
• Clarification and documentation of decisions 
• Checking and documentation of the understanding of the patient 
• If necessary, explicit postponement of the decision 
• Arrangement of follow-up meetings to check implementation and impact of decision 
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